Tolerance to benzodiazepines develops as the brain adapts to continued exposure to the drug. Over time, changes in GABA-A receptor function and neural circuits reduce the drug’s effects, so larger or more frequent doses may be needed to achieve the same level of relief or sedation. In practice, noticeable tolerance to common benzodiazepine effects often emerges after months of daily use rather than days. By about six months of ongoing use, many patients experience diminished response to the same dose across several effects (anxiolysis, sedation, amnesia, etc.), making the six-month timeframe a reasonable expectation for tolerance to accumulate. This is why the option stating tolerance can develop within six months is the best choice. It’s important to distinguish tolerance from dependence: tolerance is a reduced effect requiring dose changes, whereas dependence involves withdrawal symptoms and physiological adaptation upon stopping. Shorter intervals (like a few days) are generally too early for broad tolerance to have developed, and “never” isn’t accurate given the brain’s adaptive capacity with sustained exposure.

The YFAS is designed to be completed relatively quickly as a self-report screening. In typical administration, most respondents finish in about 10 minutes. This duration reflects enough time to read and respond to the items about eating behaviors, cravings, and related impacts without making the assessment overly burdensome in clinical or research settings. The other durations are less plausible: 2 minutes is usually not enough to thoughtfully complete all items, while 45 or 90 minutes would imply a much longer, more in-depth interview than the standard YFAS typically requires. If you’re using the full YFAS 2.0 in some contexts, it can take somewhat longer (often around 15–20 minutes), but a common practical estimate remains around 10 minutes.

In this stage, the focus is on sustaining the new behavior and preventing relapse over the long term. After making initial changes and consolidating early gains, the individual works to keep those changes stable, integrate them into daily life, and strengthen coping skills to handle triggers and stress. Relapse prevention is central: identifying high‑risk situations, using coping strategies (urge management, distraction, problem-solving), maintaining supports (therapy, peer groups, family), and planning for slips without abandoning the change. This stage is distinct from earlier ones where the person isn’t ready to change (precontemplation), is weighing options but not yet committed (contemplation), or is actively implementing new behaviors (action). The description provided aligns with the maintenance phase, where the goal is long‑term stabilization of the new, SAMPLEhealthier behavior.

Nausea is not part of the standard tobacco withdrawal symptom cluster. When someone stops smoking, the typical withdrawal effects are insomnia, anxiety, irritability, restlessness, difficulty concentrating, depressed mood, increased appetite with potential weight gain, and strong tobacco cravings. Nausea can occur for other reasons or as a side effect of nicotine replacement therapy, but it isn’t listed as a core withdrawal symptom. Therefore, nausea is the correct choice as the item that isn’t a tobacco withdrawal symptom.

Alcohol withdrawal happens when someone who has been drinking heavily stops or reduces intake, and the brain becomes hyperactive as it readjusts. This produces a range of symptoms from mild to severe. Common features include tremors, agitation, anxiety, insomnia, tachycardia, hypertension, sweating, and nausea. As withdrawal can progress, seizures may occur within a day or two, and delirium tremens can develop with severe confusion and marked agitation, often accompanied by fever and perceptual disturbances. The option that includes agitation, fever, seizures, tremors, confusion, and delusions fits this spectrum, capturing both the autonomic and neurologic signs seen with withdrawal and the potential delirium stage. The other options don’t describe the withdrawal pattern: nausea and lightheadedness alone are too limited; chronic cough and wheezing point to respiratory disease; hyperactivity and euphoria suggest stimulant effects, not withdrawal.